Xechem International Inc. (fka XKEM)

[painkillerdoc]

Smart., RE. Biotechs valued, based on future earnings.

This is very true of Biotechs, and especially so of those that have reached this stage.

Effectiveness of the product approved for sale, in this case Nigeria, where the largest number of SCD sufferers reside in one country, and upwards of 5 million there alone, is first and foremost the deciding factor in validation of Xkem and their success, in conjunction with their being an emerging Biotech.

Putting aside all arguments for a moment here on this MB. Consider those SCD sufferers currently being treated with Nicosan, free of the pain and the effects of recurring episodes.
Ask how they feel? Ask Investor Relations for this answer.
This is what is truly astounding about XKEM.

Will this board degenerate into a bashers paradise?
Fear and Greed abound here in a multiple of varieties.